T-Cell Cytokine-Inducing Surface Molecules and Methods of Use
OwnerCarl Keith Edwards, III, Li Li +2inventors
InventorsCarl Keith Edwards, III, Li Li, Karen R. Jonscher, David Norris
Life of this patent
Estimating the term…
Abstract
The invention provides cytokine modulators and methods for using the same to modulate cytokine production in monocyte lineage-derived cells. In particular, cytokine modulators of the invention selectively bind to a T-cell cytokine-inducing surface molecule (TCISM)-ligand of T lymphocytes or the corresponding TCISM-receptor of monocyte lineage-derived cells, thereby modulating cytokine production in monocyte lineage-derived cells.
Claims20
A method for modulating cytokine production in monocyte lineage-derived cells of a subject comprising administering a cytokine modulator to said subject, wherein the cytokine modulator selectively binds to a T-cell cytokine-inducing surface molecule (TCISM)-ligand of a T lymphocyte or the corresponding TCISM-receptor of a monocyte lineage-derived cell, whereby binding of the cytokine modulator to the TCISM-ligand or the TCISM-receptor modulates cytokine production in monocyte lineage-derived cells.
A method for treating a clinical condition mediated by acute or chronic inflammation in a subject comprising administering a cytokine modulator to said subject, wherein the cytokine modulator selectively binds to a T-cell cytokine-inducing surface molecule (TCISM)-ligand of T lymphocytes or the corresponding TCISM-receptor of monocyte lineage-derived cells, whereby modulation of cytokine production by the cytokine modulator is used to treat the clinical condition mediated by acute or chronic inflammation.
A method for treating an autoimmune disease in a subject comprising administering a therapeutically effective amount of an antagonist to a TCISM-ligand or an antagonist to the corresponding TCISM-receptor to the subject in need of such treatment.
A method for modulating cytokine production in monocyte lineage-derived cells of a subject comprising administering a siRNA to said subject, wherein the siRNA inhibits transcription of a gene for a T-cell cytokine-inducing surface molecule (TCISM)-ligand of a T lymphocyte, whereby inhibition of transcription of the TCISM-ligand reduces cytokine production in the subject.
Dependencies are inferred from the claim text.